November 13-15, 2018

Boston, MA, USA

Twitter logo for website footers 2

Day One
Wednesday 14th November

Day Two
Thursday 15th November

08.00
Registration & Morning Refreshments

09.00
Chairman’s Opening Remarks

Novel Approaches to Understand Complement in Physiology and Disease

09.30
In Vivo Imaging of Arthritic Joints Reveals a New Function for an Old Mediator

  • Andrew Luster Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital

Synopsis

  • C5a and C5aR are required for immune-complex induced inflammatory arthritis
  • C5a generated in the joint is transcytosed and presented on joint endothelium to blood borne leukocytes
  • C5aR initiates neutrophil arrest on joint endothelium required for transendothelial migration and entry into the joint

10.00
Inhibition of Essential Gram-negative Bacterial Membrane Biogenesis Pathways to Enhance Complement-mediated Clearance

  • Sharookh Kapadia Sr. Scientist and Project Team Leader, Infectious Diseases, Genentech

Synopsis

  • Bacteria have evolved multiple mechanisms to resist immune recognition and killing in vivo, in particular against complement-mediated lysis and clearance
  • Develop novel antibacterial therapies to treat unmet Gram-negative bacterial infections by targeting essential bacterial pathways that, when regulated, lead to enhanced immune-mediated clearance
  • Determine if targeting specific essential outer membrane biogenesis pathways in bacteria leads to enhanced complement-dependent clearance

10.30
Morning Refreshments and Poster Session

Optimize Therapeutics with Pathway-specific Targeting in Common Disease Indications

11.30
Complement and C1 Inhibitor in Solid Organ Transplantation

  • Mel Berger Senior Medical Director, Immunology R&D, CSL Behring

Synopsis

  • Complement plays important roles in ischemia-reperfusion injury-delayed graft function and in antibody-mediated rejection of solid organ allografts
  • Complement is also likely involved in increasing allo-sensitization/immunologic memory
  • Clinical trial data suggests that C1-Inhibitor may be beneficial in ameliorating the adverse effects of complement activation in solid organ transplantation

12.00
Targeting C5a for Chronic and Autoimmune Inflammatory Diseases

Synopsis

  • Explore the MoA of C5a and its potential as target in inflammatory diseases
  • Discuss IFX-1, first-in-class anti-human C5a monoclonal antibody which is being developed in chronic inflammatory diseases
  • Discuss ongoing clinical trials and reflect on progress in common indications

12.30
HMR59 for the Treatment of Age-related Macular Degeneration

  • Adam Rogers Chief Executive Officer, Hemera Biosciences

Synopsis

  • Blocking complement at Membrane Attack Complex
  • HMR-1001 6-month results for the treatment of dry AMD
  • HMR-1002 for the treatment of wet AMD

12.50
Leadership Q&A Session

Synopsis

Discussion session with expert speakers to discuss their preclinical and clinical developments in common indications.

Topics to be discussed:

  • What common disease indication has the most potential for clinical success?
  • How much inhibition is necessary to control disease and reduce safety risks?

12.50
Lunch & Networking

13.50
Panel Discussion: Identify Which Indication will Benefit Most from Complement Therapeutics to Maximize Clinical Efficacy

Synopsis

• What common disease indication has the most potential for clinical success?
• How much inhibition is necessary to control disease and reduce safety risks?
• Rationale behind which complement complex to target

14.50
Afternoon Refreshments

15.20
Complement Factor B Inhibitor, IONIS-FB-LRX, for Age-Related Macular Degeneration

  • Michael McCaleb Vice President, Clinical Development, Ionis Pharmaceuticals

Synopsis

  • Explore the results of complement factor B inhibition in healthy volunteers
  • Assess the results of FB antisense oligonucleotides (ASO) in various common disease indications
  • Discuss the clinical analyses of complement in phase 1 studies

15.20
Leadership Q&A Session

  • Michael McCaleb Vice President, Clinical Development, Ionis Pharmaceuticals
  • Frank Baas Chief Scientific Officer, Complement Pharma

Synopsis

Discussion session with expert speakers to discuss their preclinical and clinical developments in common indications.

Topics to be discussed:

  • Rationale behind which complement complement complex to target
  • What challenges are associated with complement therapy for CNS disorders?

15.50
The Role of Complement, especially the Membrane Attack Complex, in Neurological Disorders

  • Frank Baas Chief Scientific Officer, Complement Pharma

Synopsis

  • MAC deposition in neurological disorders
  • Development of MAC inhibitors
  • The effect of inhibitors on the terminal pathway in preclinical models

16.20
Chairman’s Closing Remarks

16.30
End of Day Two